Abbott Laboratories $ABT Stock: Public Sector Pension Investment Board Increases Position

Abbott Laboratories logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Public Sector Pension Investment Board increased its Abbott stake by 32.7% in the third quarter, adding 448,744 shares to reach 1.82 million shares valued at about $187.8 million.
  • Abbott reported quarterly EPS of $1.42, in line with estimates, and revenue of $13.01 billion, up 14.5% year over year. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $118.32.
  • The company’s quarterly dividend was $0.63 per share, equivalent to an annualized $2.52 and a 2.4% yield.
  • Five stocks to consider instead of Abbott Laboratories.

Public Sector Pension Investment Board raised its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 32.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,821,369 shares of the healthcare product maker's stock after purchasing an additional 448,744 shares during the period. Public Sector Pension Investment Board owned 0.11% of Abbott Laboratories worth $187,838,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Manning & Napier Advisors LLC purchased a new position in shares of Abbott Laboratories during the second quarter valued at approximately $31,000. Foresight Capital Management Advisors Inc. purchased a new stake in Abbott Laboratories in the third quarter worth $31,000. Balance Wealth Partners LLC purchased a new stake in Abbott Laboratories in the third quarter worth $34,000. Summit Securities Group LLC boosted its holdings in Abbott Laboratories by 41.3% in the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker's stock valued at $37,000 after acquiring an additional 118 shares in the last quarter. Finally, Addison Advisors LLC bought a new stake in Abbott Laboratories in the second quarter valued at $40,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Mary Moreland sold 3,500 shares of the company's stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $116.00, for a total value of $406,000.00. Following the sale, the executive vice president directly owned 100,791 shares of the company's stock, valued at $11,691,756. This represents a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Trading Down 2.6%

NYSE ABT opened at $104.64 on Wednesday. The firm has a market capitalization of $181.23 billion, a PE ratio of 39.04, a P/E/G ratio of 1.88 and a beta of 0.54. The stock's 50 day moving average is $103.89 and its 200 day moving average is $101.74. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $132.02. The company has a quick ratio of 1.00, a current ratio of 1.45 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.42. The business had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The firm's quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.30 earnings per share. Research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 16th. Stockholders of record on Thursday, October 15th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Thursday, October 15th. Abbott Laboratories's payout ratio is 94.03%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ABT shares. Barclays began coverage on shares of Abbott Laboratories in a research report on Wednesday, October 7th. They set an "overweight" rating and a $120.00 price objective on the stock. JPMorgan Chase & Co. cut their target price on shares of Abbott Laboratories from $120.00 to $118.00 and set an "overweight" rating on the stock in a research note on Thursday, October 22nd. Argus cut shares of Abbott Laboratories from a "buy" rating to a "hold" rating in a research report on Tuesday, October 27th. BTIG Research reduced their price target on shares of Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating on the stock in a research report on Thursday, October 22nd. Finally, Weiss Ratings raised shares of Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $118.32.

View Our Latest Stock Analysis on ABT

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott's offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Read More

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Abbott Laboratories Right Now?

Before you consider Abbott Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.

While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines